By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Abeona Therapeutics 



Cleveland  Ohio    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Abeona Therapeutics Reports First Quarter 2017 Financial Results And Recent Business Highlights 5/16/2017 8:31:33 AM
Abeona Therapeutics Announces Top-Line Data For ABO-102 Phase I/II MPS IIIA Gene Therapy Trial At ASGCT 5/12/2017 7:53:25 AM
Abeona Therapeutics Receives Regulatory Approval To Initiate Clinical Trial In Australia With ABO-102 Gene Therapy For Patients With MPS IIIA 5/10/2017 12:07:36 PM
Abeona Therapeutics Receives Regulatory Approval To Initiate Clinical Trial In Australia With ABO-102 Gene Therapy For Patients With MPS IIIA 5/9/2017 9:44:16 AM
Abeona Therapeutics Provides Update On EB-101 Gene Therapy For Severe Form Of Epidermolysis Bullosa From The Society For Investigative Dermatology Conference 5/2/2017 10:16:04 AM
Abeona Therapeutics Announces EB-101 Clinical Update To Be Presented At The Society For Investigative Dermatology Annual Meeting 4/25/2017 1:14:26 PM
Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 3/8/2017 8:09:13 AM
Abeona Therapeutics Provides Update From ABO-102 Phase I/II MPS IIIA Clinical Trial At The 13th Annual WORLDSymposium 2017 2/17/2017 8:30:29 AM
Abeona Therapeutics Enrolls First High Dose Subject In Ongoing Phase 1/2 Gene Therapy Clinical Trial In Sanfilippo Syndrome Type A 2/1/2017 7:20:25 AM
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017 1:52:02 PM
12
//-->